학술논문
Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
Document Type
Article
Author
Source
In: Oncotarget . (Oncotarget, 2017, 8(61):103014-103031)
Subject
Language
English
ISSN
19492553